Data_Sheet_1_Bleomycin Revisited: A Direct Comparison of the Intratracheal Micro-Spraying and the Oropharyngeal Aspiration Routes of Bleomycin Administration in Mice.PDF

Idiopathic Pulmonary Fibrosis (IPF) is a fatal disease characterized by exuberant deposition of extracellular matrix components, deterioration of lung architecture and impairment of lung functions. Its etiopathogenesis remains incompletely understood, as reflected in the lack of an appropriate therapy. Modeling the human disease in mice via the administration of bleomycin (BLM), despite the inherent limitations, has provided valuable insights into the underlying pathogenetic mechanisms, and has been instrumental for the development and validation of new pharmacologic interventions. Here we have directly compared the, most widely used, intratracheal (IT) route of administration with oropharyngeal aspiration (OA). Our results suggest that the OA route of BLM-administration can be used as a safe and effective alternative, minimizing peri-operative and experimental mortality, while preserving a solid fibrotic profile, as assessed with a plethora of standardized readout assays.

特发性肺纤维化（Idiopathic Pulmonary Fibrosis, IPF）是一种致命性疾病，其特征为细胞外基质成分过度沉积、肺组织结构破坏及肺功能受损。由于目前缺乏有效的治疗手段，该病的发病机制尚未完全阐明。尽管通过给予博莱霉素（bleomycin, BLM）在小鼠体内构建人类疾病模型存在固有局限性，但该方法仍为揭示潜在致病机制提供了重要见解，并对新型药理学干预手段的开发与验证起到了关键作用。本研究直接对比了目前应用最为广泛的气管内（intratracheal, IT）给药途径与口咽抽吸（oropharyngeal aspiration, OA）给药途径。结果表明，BLM经口咽抽吸给药可作为一种安全有效的替代方案，该方法可降低围手术期及实验动物死亡率，同时通过多项标准化检测终点实验证实，其仍可维持稳定的纤维化表型。